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Abstract
Background: Human embryonic stem cells (hESCs) partially recapitulate early embryonic three germ layer
development, allowing testing of potential teratogenic hazards. Because use of hESCs is ethically debated, we
investigated the potential for human induced pluripotent stem cells (hiPSCs) to replace hESCs in such tests.
Methods: Three cell lines, comprising hiPSCs (foreskin and IMR90) and hESCs (H9) were differentiated for 14 days.
Their transcriptome profiles were obtained on day 0 and day 14 and analyzed by comprehensive bioinformatics tools.
Results: The transcriptomes on day 14 showed that more than 70% of the “developmental genes” (regulated genes
with > 2-fold change on day 14 compared to day 0) exhibited variability among cell lines. The developmental genes
belonging to all three cell lines captured biological processes and KEGG pathways related to all three germ layer
embryonic development. In addition, transcriptome profiles were obtained after 14 days of exposure to teratogenic
valproic acid (VPA) during differentiation. Although the differentially regulated genes between treated and untreated
samples showed more than 90% variability among cell lines, VPA clearly antagonized the expression of developmental
genes in all cell lines: suppressing upregulated developmental genes, while inducing downregulated ones. To quantify
VPA-disturbed development based on developmental genes, we estimated the “developmental potency” (Dp) and
“developmental index” (Di).
Conclusions: Despite differences in genes deregulated by VPA, uniform Di values were obtained for all three cell lines.
Given that the Di values for VPA were similar for hESCs and hiPSCs, Di can be used for robust hazard identification,
irrespective of whether hESCs or hiPSCs are used in the test systems.
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Background
Drug-induced embryotoxicity, manifested as teratogen-
icity, is a major safety issue. At present, various in vivo
and in vitro assays are used for testing for adverse
teratogenic effects of potential drug candidates. How-
ever, the present transitional teratogenicity assessment
methods are limited because: (1) interspecies differences
in both in vitro and in vivo animal-based test systems do
not optimally predict human relevant teratogenic drug
candidates; (2) traditional methodologies involve exten-
sive animal studies, making tests costly and time-
consuming; and (3) traditional approaches are not
efficient given that they only allow testing of a limited
number of compounds at a time, even though the num-
ber of the drug candidates increases markedly each year
(http://cen.acs.org/articles/94/i5/Year-New-Drugs.html).
Such limitations have resulted in several drugs being
withdrawn from the market because of toxic effects to
humans [1]. To overcome these limitations novel in vitro
testing systems are urgently needed [2–7]. Recently, tre-
mendous efforts have been made to develop in vitro test
systems for identifying teratogenic effects of drug candi-
dates based on human embryonic stem cells (hESCs)
and human induced pluripotent stem cells (hiPSCs), as
reviewed in [8–10]. Both in vitro hESC-based systems
developed by the University of Konstanz (UKN) and
Universitätsklinikum Köln (UKK) recapitulate the crit-
ical phases of embryonic development, during which
cells can be exposed to various test compounds [11].
These systems have already been applied in numerous
studies to identify and characterize developmental toxi-
cants [12–15].
More recently, the UKN and UKK test systems have been
upgraded to so-called -omics prediction test systems
(STOP-Tox), allowing quantification of the developmental
toxicity of a compound, based on microarray gene expres-
sion data [10]. In the UKK test system, which partially
recapitulates early embryonic development at transcripto-
mics level, H9 hESCs were randomly differentiated for
14 days to three germ layers and their derivatives [13–15].
The differential regulated genes on day 14 of differentiation
compared with undifferentiated hESCs (day 0) were identi-
fied using genome-wide microarrays and were designated
as “developmental” probe sets or “developmental” genes.
Moreover, the influence of six mercurials and six histone
deacetylase inhibitors on these developmental genes was
quantified using two basic indices, “developmental potency”
(Dp) and “developmental index” (Di). Both Di and Dp quan-
titatively predict and discriminate the toxicity effects of
various chemicals on embryonic development. This
recently developed STOP-ToxUKK test is based on hESCs
[10]. However, there is an ongoing ethical debate over the
use of hESCs for embryotoxicity testing [16]. The discovery
of hiPSCs [17] provides an alternative to hESCs for toxicity
testing. In this context, very few studies are available apply-
ing hiPSCs as a model for developmental neurotoxicity (for
review see [18, 19]). Although hiPSCs are most similar to
hESCs, small differences still exist in their epigenetic land-
scape, transcribed genes, and differentiation potential [20].
In the present study, we investigated whether hESCs can be
replaced by hiPSCs to develop a sensitive developmental
test system. Here, we systematically compare the develop-
mental toxicity potency of valproic acid (VPA) on two
hiPSC-based cell lines (foreskin and IMR90) along with H9,
using transcriptomics and comparative bioinformatics.
Methods
Materials
The H9 hESCs (as WA09 line), foreskin hiPSCs (clone 4)
and IMR90 hiPSCs (clone 4) were obtained from WiCell
(Madison, WI, USA). H9 hESCs were cultured on irradi-
ated mouse embryonic fibroblasts in a culture medium, as
described in [15]. BD Matrigel matrix (354277) and BD
Matrigel growth factor reduced (354230) used for
culturing were from BD Biosciences (San Jose, CA, USA).
All cell culture reagents were from Gibco/Invitrogen
(Darmstadt, Germany), unless otherwise specified. VPA
(P4543) and Pluronic F-127 (P2443) were obtained from
Sigma-Aldrich (Steinheim, Germany).
Random differentiation of stem cells to germ layer cell
types and their derivatives
To remove the mouse embryonic fibroblasts, the H9
hESCs were transferred from the maintenance culture
onto hESC-qualified matrix (BD Biosciences) -coated
60-mm tissue culture plates (Nunc, Langenselbold,
Germany) in TESR1 medium (Stem Cell Technologies,
Vancouver, BC, Canada). The hiPSCs (foreskin and
IMR-90) were maintained on 60-mm tissue culture
plates coated with BD Matrigel growth factor reduced in
TESR1 medium. Cells were maintained on these plates
for 5 days prior to differentiation. The random differen-
tiation of hESCs was performed using the embryoid
bodies protocol, as described previously [15]. Briefly, the
clumps were obtained by cutting and scraping the cells
with passage scrapers (StemPro EZPassageTM Dispos-
able; Invitrogen, Carlsbad, CA, USA). On day 0, 100
clumps were seeded in a conical well, coated with Pluro-
nic F-127 (5%) in 100 μl of random differentiation
medium (Dulbecco’s modified Eagle’s medium (DMEM)-
F12 medium with 20% KO serum replacement, 1% non--
essential amino acids, penicillin (100 units/ml), strepto-
mycin (100 μg/ml), 0.1 mM β-mercaptoethanol)
containing 1 mM VPA or vehicle, and incubated for
4 days at 37 °C and 5% CO2. The embryoid bodies were
collected on day 4 and transferred onto 100-mm bac-
teriological plates in 15 ml of random differentiation
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medium containing 1 mM VPA or vehicle. The medium
was replenished every alternate day, until day 14.
Microarray experimental details
Cell RNA isolation was performed, as previously reported
[14, 21]. Briefly, total RNA was isolated using TRIzol and
chloroform (Sigma-Aldrich) and purified with miRNeasy
mini kit (Qiagen, Hilden, Germany). All quantification
and quality measurements were performed using a Nano-
Drop spectrophotometer (ND-1000; Thermo Fisher Scien-
tific, Langenselbold, Germany). For microarray labelling,
100 ng total RNA was taken as a starting material, and
after amplification, 12.5 μg-amplified RNA was hybridized
on Affymetrix Human Genome U133 Plus 2.0 arrays
(Affymetrix, Santa Clara, CA, USA). For washing and
staining, Affymetrix HWS kit and Genechip Fluidics
Station 450 were used, according to the manufac-
turer’s instructions. After staining, arrays were
scanned with Affymetrix GeneChip Scanner 3000 7G
and Affymetrix GCOS software was used for quality
control analysis.
Statistical data and functional annotation analysis
Microarrays statistical data analysis and visualization
were carried out by uploading. CEL files in Partek
Genomics Suite (PGS) version 6.6 (Partek, St. Louis,
MO, USA). The probe sets intensity values were obtained
after RMA background correction, quantile normalization,
log2 transformation, and median polished probe sets
summarization. The normalized probe sets were used for
principal component analysis (PCA), while a one-way
ANOVA model was used to generate the differentially reg-
ulated transcripts, with at least a twofold change using the
Benjamini and Hochberg false discovery rate (FDR) cor-
rection (p ≤ 0.05). The signals of differentially regulated
probe sets were normalized using their Z scores and were
clustered using unsupervised hierarchical cluster analysis.
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) was used for gene ontology categories
(GOs) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analysis of differentially expressed
transcripts [22, 23].
Dp and Di were calculated as per the formula
Dp ¼ OD and Di ¼ OATD (for details of the terms please
refer Fig. 3).
Results
Data structure of developmental and valproic acid-
deregulated genes in differentiating stem cells
Both hESCs and hiPSCs were differentiated for 14 days.
Gene expression profiles were analyzed for hESCs and
hiPSCs on day 0 and day 14 (Fig. 1a). To compare the
differentiation potential of hESCs with hiPSCs and to
quantify their resemblance with specific human cell
types, we performed a gene regulatory network analysis
using CellNet [24]. CellNet showed embryonic stem cell
(ESC) scores higher than 0.95 for hESCs and hiPSCs on
day 0, indicating relatively similar transcriptome profile
of hESC and both hiPSC cell lines with standard hESCs.
Differentiation over 14 days resulted in a significant
decrease in the ESC score, indicating variable differenti-
ation of hESCs and hiPSCs. IMR90 hiPSCs had lower
ESC scores than foreskin hiPSCs and H9 hESCs (Fig. 1b).
Although the increase in tissue classification scores was
relatively small for all three cells lines, there were a few
striking differences observed among them (Additional
file 1: Figure S1). On day 0 and day 14 of differentiation,
foreskin and IMR90 hiPSCs showed higher scores for fi-
broblasts than hESCs. Similarly, their scores were higher
for lung on day 14. IMR90 had highest scores for skin,
heart and kidney on day 14 of differentiation (Additional
file 1: Figure S1). During differentiation, cells were
exposed to 1 mM VPA from day 0 to day 14 and gene
expression profiles from day 0 and 14 were compared
with time-matched controls (Fig. 1a). To obtain an over-
view of this genome-wide data, PCA plots were pre-
pared. Differentiation over 14 days resulted in relatively
large spread within the PCA plot, although all three cell
types shifted in a similar direction under treatment
(Additional file 1: Figure S2). PCA plots based on differ-
entially regulated genes on day 14 compared with day 0
(Additional file 2: Table S1) and differential genes
induced by VPA on day 14 (Additional file 2: Table S2)
were prepared. This PCA plot shows only small differ-
ences between hESCs and hiPSCs on day 0 (Fig. 1c).
Our analysis illustrates a relatively large shift among the
controls for all three cell lines between day 0 and day
14, occurring along the first principle component axis.
In contrast, VPA-induced effects led to a shift predomin-
antly along the second principle component axis (Fig. 1c).
The differentially regulated genes on day 14 with respect
to day 0 (having an absolute fold change ≥ 2 and FDR-
corrected p value < 0.05) in H9 hESCs, IMR90 and fore-
skin hiPSCs are further referred as “developmental
genes” (Fig. 1d). The number of developmental genes
was much higher than the genes deregulated by VPA on
day 14 (Fig. 1f ). The overlap of developmental genes
among the three cell lines shows that 26% are common
up- or downregulated genes that means variability
amongst them is > 70% (Fig. 1e). In contrast, overlap of
VPA-deregulated genes captured only 8% of up- and 1%
of downregulated genes among hESCs and hiPSCs that
means variability amongst them is > 90% (Fig. 1g).
Cluster analysis based on Z scores for VPA-deregulated
genes (absolute fold change ≥ 2, FDR-corrected p value <
0.05) led to distinct clusters for day 0 and day 14, irre-
spective of cell line (Fig. 1h). VPA-exposed samples did
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not lead to independent branches, but rather clustered
close to their respective controls (Fig. 1h).
Characterization of developmental genes of stem cells
The biological processes significantly influenced by
developmental genes were assessed for overrepresented
GOs (Additional file 2: Tables S3 and S4). Overrepre-
sented GOs were subdivided into developmental (associ-
ated with embryonic development) or non-developmental
GOs (associated with cellular homeostasis). Downregu-
lated developmental genes contributed to less than 4%
developmental and less than 25% non-developmental
GOs, whereas upregulated developmental genes contrib-
uted to more than 30% developmental and non-
developmental GOs in H9 hESCs versus foreskin and
IMR90 hiPSCs (Fig. 2a). These results demonstrate that a
similarly high number of developmental and non-
developmental GOs are covered by upregulated develop-
mental probe sets in all three cell lines. In contrast, only a
few developmental GOs have been identified among the
downregulated PS, although a relatively high number of
non-developmental genes occur in all three differentiated
cell lines. These results show that more upregulated devel-
opmental GOs are necessary to drive all three cell lines to
more specialized somatic cell types than downregulated
developmental GOs, which are necessary only for regula-
tion of the pluripotent stage. Consequently, because gen-
eral non-developmental processes associated with cellular
homeostasis (e.g., metabolism, cell proliferation) occur in
all cell types, a high number of downregulated non-
developmental GOs would also be expected. Overlap ana-
lysis of GOs captured by upregulated developmental genes
shows almost 47% overlap between hESCs and hiPSCs
(Fig. 2b). For downregulated developmental genes, only
21% of overrepresented GOs overlap all three cell lines
(Fig. 2c). Overall, 64% up- or downregulated GOs were in
the overlap region between differentiated H9 ESCs and
foreskin hiPSCs; while only 50% of up- and 21% of
downregulated genes overlap between H9 hESCs and
IMR90 hiPSCs; and 48% of up-, and 28% of downregu-
lated GOs overlap between foreskin and IMR90 hiPSCs
(Fig. 2b, c). The higher overlap observed for GOs (Fig. 2b,
c) compared to probe sets (Fig. 1e, g) shows that although
different genes are involved in hESCs and hiPSCs, they
nevertheless fall into similar GOs. For upregulated devel-
opmental genes, significantly overrepresented KEGG
pathways include focal adhesion, Erb signalling, Wnt
signalling, TGF-β signalling, and the Hedgehog pathway
in H9 hESCs, as well as in both hiPSCs (Fig. 2d). These
pathways are known to be involved in embryonic devel-
opment. Significantly overrepresented KEGG pathways
for downregulated developmental genes include MAPK
signalling, tight junction, glycolysis, cell adhesion
molecules, and focal adhesion in all three cell lines. Erb
signalling, VEGF signalling, arginine and proline metab-
olism were overrepresented only in H9 hESCs and the
IMR90 hiPSCs (Fig. 2e). Moreover, germ layer-specific
genes among the developmental genes were analysed
using Partek Genomics Suite (Additional file 2: Table
S5). High numbers of developmental genes (up- and
downregulated) of differentiated hESCs, IMR90 and
foreskin hiPSCs were ectoderm- and mesoderm-
specific, as opposed to endoderm-specific (Fig. 2f ).
Common ectodermal upregulated and downregulated
genes among all three cell lines were TFAP2A, ATP7A,
PAX6, LEF1, DCT, BCL2, POU3F2, APC, COL5A2 and
BTD, PDGFA, FRAS1, PPL, NF2, respectively. Common
upregulated and downregulated mesodermal genes
were DLL3, EXT1, FOXC1, LEF1, LHX2, SMAD3,
BMP4, SNAI2, SMAD1, SLIT2 and NF2, FOXH1,
MATK, HCK, TCF7L1, respectively. The only common
upregulated endodermal gene was EXT1. These results
indicated that all three cell lines mainly captured ecto-
dermal and mesodermal genes within 14 days of differ-
entiation, with several of these genes common among
all cell lines.
(See figure on previous page.)
Fig. 1 Global analysis of the valproic acid (VPA)-induced differentially expressed genes in human embryonic stem cells (hESCs) and human
induced pluripotent stems cells (hiPSCs). a hESCs and hiPSCs were differentiated towards all three germ layers and their derivatives for 14 days in
the presence and absence of VPA. Samples from three biological replicates were collected on day 0 and day 14 for the microarray studies. b
CellNet analysis of the.CEL files shows the ESC classification score, which represents the pluripotency status of hESCs and hiPSCs on day 0 and
differentiated cells at day 14. c Two-dimensional principle component analysis (2D-PCA) of differentially expressed genes (hESCs or hiPSCs at day
0 vs 14 days of differentiation, absolute fold change≥ 2, p < 0.05; 14-day differentiated hESCs or hiPSCs in the presence and absence of VPA, with
absolute fold change≥ 2, p < 0.05). The PCA illustrates a significant variance in the gene expression level in PC1 from day 0 to day 14 in the
absence of VPA, whereas PC2 represents variance in the expression level of genes induced by VPA. d “Developmental” probe sets are defined as
differentially expressed probe sets on day 14 of differentiation, compared with undifferentiated H9 hESCs, values are for foreskin hiPSCs and the
IMR90 hiPSCs on day 0 (absolute fold change≥ 2, FDR corrected p value < 0.05). e Venn diagram of the developmental PS, showing up- and
downregulated genes. f, g Numbers and Venn diagrams of the differentially expressed probe sets (absolute fold change≥ 2, FDR-corrected p
value < 0.05) after exposure to VPA for 14 days, compared with 14-day differentiated H9 hESCs, foreskin hiPSCs and IMR90 hiPSCs. h Hierarchical
cluster analysis of significantly deregulated transcripts (absolute fold change≥ 2, p < 0.05) in 14-day untreated versus VPA-treated cells (Partek
Genomics Suite). The results are represented as a heatmap, with gene expression level of the probe set given by blue: low; and red: high
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Fig. 2 Characterization of differentially regulated probe sets at day 14 of differentiation in the human embryonic stem cells (hESCs) and human
induced pluripotent stem cells (hiPSCs). a The differentially expressed (absolute fold change≥ 2, false discovery rate (FDR)-corrected p value
< 0.05) probe sets at day 14, called developmental probe sets were further characterized using the online tool ‘DAVID’. The gene ontology
categories (GOs) belonging to biological processes (BPs) overrepresented among the up- and downregulated probe sets (p < 0.05) were further
subcategorized into two classes: “developmental” and “non-developmental” GOs. The numbers of the overrepresented GOs for up- and
downregulated genes in hESCs and hiPSCs are shown on the top of each bar. b, c Venn diagrams indicating the intersections for up- or
downregulated developmental GOs, among hESCs and hiPSCs, respectively. d, e KEGG pathways associated with the up- or downregulated
developmental probe sets, respectively. Numbers indicate the total number of probe sets (*FDR-corrected; p value < 0.05). f Overlap analysis of
the well-annotated three germ layer-specific genes obtained from Partek Genomics Suite, showing overlap among the developmental genes. The
total number of the deregulated probe sets is indicated on the top of each column
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Comparison of gene expression in undifferentiated stem
cells (day 0)
To compare the pluripotency state of the two hiPSCs
with the pluripotency state of hESCs, a comparison of
their transcriptomes at day 0 was performed, and differ-
entially regulated genes (absolute fold change ≥ 2, FDR-
corrected p value < 0.05) were identified (Additional file
2: Table S6). Among the key pluripotency related genes
(POU5F1, NANOG, SOX2, and KLF4), only the expres-
sion level of KLF4 was found higher in foreskin hiPSCs,
as compared to H9 hESCs and IMR90 hiPSCs undiffer-
entiated cells, whereas the expression levels of POU5F1,
NANOG, SOX2 was very similar in all three cell lines.
There was no significant difference observed for KLF4
between undifferentiated H9 hESCs and IMR90 hiPSCs.
Moreover, five mostly upregulated genes, DDX3Y, EIF1AY,
USP9Y and RPS4Y1 (located in the Y chromosome) were
highly upregulated in foreskin hiPSCs, compared to H9
ESCs or IMR90 hiPSCs (>60-fold change, p value < 7.4E-
20). XIST (located in the X-chromosome) was found to be
markedly downregulated in foreskin hiPSCs, compared to
IMR90 hiPSCs and the hESCs. These findings reflect the
fact that the foreskin hiPSCs are from a male (karyotype
of XY), while both H9 hESCs and IMR90 hiPSCs are from
females (XX karyotype).
Characterization of valproic acid-deregulated genes in stem
cells
The influence of VPA on both hiPSC lines and H9 hESCs
was small compared with effects related to up- or down-
regulation of developmental genes during the 14-day dif-
ferentiation period, as evident from the PCA (Fig. 1c). The
number of VPA-deregulated probe sets (Fig. 1f; Additional
file 2: Table S2) was relatively low compared to the devel-
opmental probe sets (Fig. 1d; Additional file 2: Table S1).
The biological processes significantly influenced by VPA
also were analysed for overrepresented GOs (Additional
file 2: Tables S7 and S8). Overrepresented GOs were fur-
ther subdivided into developmental or non-developmental
GOs. Using this subdivision, we observed that the VPA-
induced downregulated genes captured more develop-
mental GOs, compared to VPA-induced upregulated
genes in all three cell lines (Fig. 3a). Overlap analysis of
GO groups overrepresented in VPA-deregulated genes for
all three cell lines showed only 16% overlap for up- and
4% for downregulated probe sets (Fig. 3b, c). The common
up- or downregulated GOs (see Additional file 2: Tables
S7 or S8, respectively) observed in three cell lines included
“anatomical structure”, and “nervous system develop-
ment” versus “neurogenesis”, “brain development”, and
“neuron differentiation”, respectively. KEGG pathway ana-
lysis identified “cell adhesion molecules” as an overrepre-
sented motif in all three cell lines (Fig. 3d). In particular,
the KEGG pathways regulated by VPA in differentiated
hESCs were more similar to the differentiated foreskin
hiPSCs than to IMR90 hiPSCs (Fig. 3d). Several common
germ layer-specific genes were identified within the devel-
opmental genes (Fig. 2f). An Venn diagram of the VPA-
deregulated germ layer-specific developmental genes
(Fig. 3e) shows that only a few common ectoderm genes
were downregulated in all three cell lines, although a few
mesodermal genes were downregulated in both hiPSC
lines (Fig. 3e; Additional file 2: Table S5). Our results sug-
gest that most of the specific germ-layer formation genes
are not deregulated by VPA. Apparently, VPA disturbs the
expression of developmental genes that are involved in
late, and more specific, differentiation processes related to
somatic cells. Overlap analysis of the VPA deregulated
genes (Additional file 2: Table S2) with developmental
genes (Additional file 2: Table S1) demonstrates that <
15% of the developmental genes were affected by VPA in
all three cell lines (Additional file 1: Figure S3). This ana-
lysis also revealed that VPA antagonized the expression of
developmental genes: suppressing upregulated develop-
mental genes and inducing downregulated developmental
genes, irrespective of whether they were hESCs or hiPSCs
(Additional file 1: Figure S3).
Dp and Di of valproic acid in stem cells
Dp represents the fraction of all developmental genes
that are up- or downregulated, using a test compound;
while Di gives the ratio of overrepresentation of develop-
mental genes among all genes deregulated by a test com-
pound. In all three test systems, more than 5% of the
developmental genes were deregulated by VPA (Dp >
0.05; Fig. 3f ). Moreover, all three cell lines showed more
than tenfold overrepresentation of developmental genes
among all genes deregulated by VPA (Fig. 3g). Notably,
the relative changes of the Dp values (Fig. 3f ) remained
stable in all three cell lines, independent of fold change
values varying from two to ten. In contrast, the relative
Di values increased, with increasing fold change (Fig. 3g).
Using Di values makes hazard identification more sensi-
tive, because some test compounds compromise the ex-
pression of only a relatively small number of genes, but
have a high propensity to specifically deregulate develop-
mental genes. In this case, the test compound generates
a low Dp, but a high Di value [10]. We show that all
three cell lines allowed us to identify VPA as a terato-
genic compound with the same sensitivity (Fig. 3g).
However, although the Dp value for IMR90 hiPSCs was
lower than foreskin hiPSCs (Fig. 3f ), their Di values
are a little higher, having fold changes of five and ten,
respectively. Thus, IMR90 hiPSCs may allow terato-
genicity testing with a higher sensitivity than foreskin
hiPSCs. H9 hESCs had the highest indices values, al-
though their differences with values for foreskin
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Fig. 3 (See legend on next page.)
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hiPSCs were very small, suggesting that both cell sys-
tems are equivalent.
Effects of valproic acid on developmental and non-
developmental genes; correlations between stem cell types
To determine the influence of VPA on developmental
probe sets and their pairwise correlation between the
two cell lines, scatter plots were constructed by plotting
VPA-deregulated developmental probe sets (fold change
values) from one cell line (x-axis) versus another cell line
(y-axis) (Fig. 4). According to Spearman’s rank-order
criteria, ρ values from 0 to 0.19, 0.20 to 0.39, 0.40 to
0.59, 0.60 to 0.79 and 0.80 to 1.0 show a very weak,
weak, moderate, strong, and very strong correlation, re-
spectively. The values obtained from Spearman’s ρ values
indicate a moderate correlation between the VPA-
deregulated genes in foreskin hiPSCs versus H9 hESCs
(Fig. 4a), as well as between foreskin versus IMR90
hiPSCs (Fig. 4c). In contrast, a strong correlation was
obtained between VPA deregulated genes in H9 hESCs
and IMR90 hiPSCs (Fig. 4b). To assess the influence of
VPA on non-developmental PS, and determine any cor-
relations between cell lines, scatter plots were con-
structed using VPA-deregulated non-developmental
probe sets (having an absolute fold change values < 2)
(Fig. 5). The ρ values obtained from a Spearman’s rank-
order correlation indicate a weak correlation between
foreskin hiPSCs versus H9 hESCs (Fig. 5a), IMR90
hiPSCs versus H9 hESCs (Fig. 5b), as well as between
foreskin and IMR90 hiPSCs (Fig. 5c). Thus, Spearman’s
rank-order analysis indicates that VPA preferably
deregulated developmental genes, yielding fold changes
greater than five for all three cell lines (i.e., having ρ
values indicating moderate to strong correlation). In
contrast, non-developmental genes showed a weak cor-
relation, having absolute fold change values below two.
Key developmental genes influenced by valproic acid in
all three cell lines
To determine VPA-antagonized common developmental
genes in hiPSCs and hESCs, an overlap analysis was
performed for developmental upregulated or downregu-
lated genes in all three cell lines, for which expression
was regulated by VPA in opposing ways (Fig. 6a, b). Four
common developmentally upregulated transcripts, i.e.,
three genes (namely B3GALNT1, DOK6 and BCL2) and
one unannotated transcript (Affymetrix id: 233944_at),
were downregulated by VPA (Fig. 6c). Likewise, 11 com-
mon developmentally downregulated transcripts, i.e., ten
genes (namely GPR176, LRAT, NFE2L3, MICB, HSPA2,
CLDN10, PFKP, PRKCB, CD9, and OGDHL) and one
unannotated transcript (Fig. 6d, e), were upregulated by
VPA. These 15 genes have been identified as the top
developmental toxicity markers for VPA-induced toxicity
in the UKK test system.
Discussion
Recent evidence suggests that hESCs combined with a
transcriptomic approach have the potential to predict
human relevant embryotoxicity. In this context, we have
developed in vitro methods based on hESCs, using tran-
scriptomics to predict developmental toxicity of different
classes of developmental toxicants. Specifically, we tested
six histone deacetylase inhibitors and six mercury com-
pounds [11, 12, 15, 25]. Human teratogenic drugs, like
thalidomide and VPA, also have been tested using the
UKK test system, covering early and late differentiation
processes of hESCs. Their altered transcriptomic profiles
determined the teratogenic mechanisms for these drugs
[13, 14], resolving the in vivo teratogenic effect of these
drugs. Furthermore, to quantify levels of developmental
toxicity, the indices Dp and Di were established, using
several differentially expressed genes induced by terato-
genic compounds, such as thalidomide and VPA [10].
Because of the ethical concerns regarding the use of
hESCs, hiPSCs were investigated as an alternative for
human relevant in vitro toxicity testing of potential
developmental toxicants. Here, we compared transcrip-
tome responses of two different hiPSCs (foreskin and
IMR90 hiPSCs) with hESCs, using the UKK test system,
and VPA as a developmental toxicant. We quantified the
toxicity potential of VPA using both Dp and Di.
(See figure on previous page.)
Fig. 3 Characterization of valproic acid (VPA)-deregulated probe sets on day 14 of differentiation in human embryonic stem cells (hESCs) and
human induced pluripotent stems cells (hiPSCs) using gene ontology categories (GOs) and KEGG pathway analysis, as well as Dp and Di indice
values. a The differentially regulated probe sets on day 14 by VPA were compared with non-treated 14-day differentiated cells (absolute fold
change≥ 2, false discovery rate-corrected p value < 0.05). The number of up- and downregulated genes overrepresented in GOs in hESCs and
hiPSCs are shown on top of the bars. b, c Venn diagrams obtained for up- or downregulated developmental GOs, for hESCs and hiPSCs,
respectively. d KEGG pathways of the VPA regulated up- or downregulated developmental probe sets, respectively. e Overlap analysis of
well-annotated three germ layer-specific genes obtained from Partek Genomics Suite, showing the overlap among VPA-deregulated “developmental”
genes. f Values for the Dp index calculated using the ratio O/D, the Di g calculated using the ratio (O x A)/(T x D), and the significance
of overlap calculated using Fisher's exact test (***p < 0.001). In this figure, A represents the total probe sets available on the microarray
chip; O represents VPA deregulated developmental probe sets; T represents the VPA deregulated probe sets; D represent “developmental”
probe sets deregulated on day 14, compared with day 0. The total number of the deregulated probe sets in (f) and (g) is indicated on the top
of the columns
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AB
C
Spearman r: 0.48,  P value (two-tailed) P<0.0001 *** Spearman r= 0.51,  P value (two-tailed) P<0.0001 ***
Spearman r: 0.63,  P value (two-tailed) P<0.0001 *** Spearman r: 0.50,  P value (two-tailed) P<0.0001 ***
Spearman r: 0.45,  P value (two-tailed) P<0.0001 *** Spearman r: 0.48,  P value (two-tailed) P<0.0001 ***
Fig. 4 Comparison of deregulated common developmental probe sets having at least a fivefold change in expression on day 14 for human
embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) affected by valproic acid (VPA).VPA-deregulated fold change
values are plotted on x and y axes. a Upregulated (left diagram) or downregulated (right diagram) developmental genes having at least a fivefold
expression change, common to 14-day differentiated hESCs (x-axis) versus the 14-day differentiated foreskin hiPSCs. b Upregulated (left diagram)
or downregulated (right diagram) developmental” genes having at least a fivefold change in expression, common to 14-day differentiated hESCs
(x-axis) and 14-day differentiated IMR90 hiPSCs (y-axis). c Upregulated (left diagram) or downregulated (right diagram) developmental genes
having at least a fivefold change in expression common to 14-day differentiated foreskin hiPSCs (x-axis) and 14-day differentiated IMR90 hiPSCs
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According to the UKK test system, cells from all three
cell lines were differentiated for 14 days in the presence
and absence of VPA.
The PCA of the transcriptomes of day 0 and day 14
based on all microarray data showed significant differ-
ences between undifferentiated hESCs and hiPSCs (day
0) and their differentiated (14 days) cells. Interestingly,
differences in the transcriptomes were fairly uniform for
all three cell lines. The differentially expressed genes on
day 14, designated as developmental genes, showed sig-
nificant differences between the hESCs and both hiPSC
lines, although the transcriptomes in undifferentiated
hESCs, and both hiPSCs lines were very similar. A GO
analysis of the upregulated genes at day 14 encompassed
more than 30% of embryonic development-related bio-
logical processes (developmental GOs) in all three cell
lines. Further analysis of these developmental genes in
hESCs and hiPSCs revealed that approximately 50% of
these similarities were attributed to upregulated develop-
mental GOs, irrespective of whether hESCs or hiPSCs
had been differentiated. Similarities were also observed
for KEGG pathways for all three cell lines. Several com-
mon GOs, such as “anatomical system development”,
“nervous system development”, “embryonic morphogen-
esis”, related to embryonic development, were identified
in the developmental genes.
A CellNet analysis revealed almost uniform ESC scores
for all three undifferentiated cell lines on day 0, and a
uniform reduction of ESC scores on day 14 of differenti-
ation, along with an increase in cell/tissue type scores,
such as fibroblast, lung, skin, kidney, heart and liver. A
few developmental genes from all three cell lines were
from the ectoderm; mesoderm and endoderm lineages,
indicating a partial recapitulation of in vivo embryonic
development at the transcriptomic level. Our CellNet
analysis showed that hiPSCs and hESCs have similar
differentiation potential, suggesting that hiPSCs can recap-
itulate developmental processes of differentiated hESCs.
VPA has teratogenic potential, inducing spina bifida at
steady state concentrations of 0.51 ± 0.17 mM in humans.
In this study, we used a Cmax approximately two times
above this level [26, 27]. Exposure to VPA during the 14-
day differentiation period resulted in deregulation of devel-
opmental genes, with opposing induction, i.e., upregulated
developmental genes were downregulated, while downreg-
ulated developmental genes were upregulated. Very few
A B
C
Spearman r:  0.28,  P value (two-tailed) P<0.0001 *** Spearman r:  0.27,  P value (two-tailed) P<0.0001 ***
Spearman r: 0.25,  P value (two-tailed) P<0.0001 ***
Fig. 5 Comparison of common “non-developmental” deregulated genes on day 14 having gene expression levels below twofold (up- and
downregulated) in human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) affected by valproic acid (VPA).
VPA-deregulated fold change values were plotted on x and y axes. a Common “non-developmental” genes in 14 day differentiated hESCs (x-axis)
were plotted against the 14-day differentiated foreskin hiPSCs. b Common “non-developmental” genes in 14-day differentiated hESCs (x-axis) were
plotted against 14-day differentiated IMR90 hiPSCs. c Common “non-developmental” genes in 14-day differentiated foreskin hiPSCs (x-axis) were
plotted against the 14-day differentiated IMR90 hiPSCs
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VPA deregulated genes were common to all three cell
lines. We found that more downregulated genes belonged
to embryonic development-related GOs than upregulated
ones. This clearly shows the inhibitory effects of VPA on
differentiation. The common VPA upregulated develop-
mental genes in all three cell lines were associated with
anatomical structure and nervous system development,
whereas VPA downregulated developmental genes were
related to nervous system development, neurogenesis, and
brain development. These results are consistent with our
earlier published findings, demonstrating that VPA re-
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Fig. 6 Comparison of the common developmental genes observed at day 14 in all three cell lines in the absence of valproic acid (VPA) with the
VPA-deregulated genes at day 14 in each cell line (absolute fold change > 2, false discovery rate-corrected p value < 0.05). a Overlap of the
developmental upregulated genes with the VPA-induced downregulated genes (four genes; see C for fold changes). b Overlap of developmental
downregulated genes with the VPA-induced upregulated genes (11 genes; see D and E for fold changes). c Fold change values for B3GALNT1,
233944_at, DOK6, and BCL2 for all three cell lines. d Fold change values for C9orf135, GPR176, LRAT, NFE2L3, MICB, HSPA2, and CLDN10 for all three
cell lines. e Fold change values for PFKP, PRKCB, CD9 and OGDHL for all three cell lines
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genes, and upregulated axonogenesis and ventral forebrain
associated genes in differentiating hESCs [13].
However, we also noted differences between the three
cell lines in genes associated with embryonic develop-
ment and regulated by VPA. Specifically, upregulated
genes associated with neural crest cell development were
identified in differentiated H9 ESCs, whereas oligo-
dendrocyte differentiation and germ cell development
were identified in differentiated IMR90 and foreskin
hiPSCs, respectively. Downregulated genes associated
with telencephalon development were identified in
differentiated H9 hESCs, whereas genes involved in the
metencephalon development and heart tube develop-
ment were identified in IMR90 and foreskin hiPSCs,
respectively. Clearly, GOs identified in hESCs and
hiPSCs do not allow a quantification of the toxic effect
of developmental toxicants.
Given that a conclusion as to whether hiPSCs can
replace hESCs for developmental toxicity testing based
on a GO analysis is not possible, we proposed the use of
two indices: Dp and Di based on VPA deregulated devel-
opmental genes. Dp represents the intersection of VPA--
deregulated genes with developmental genes and its
value directly correlates with the developmental toxicity
potential. Di represents the ratio of developmental genes
among VPA deregulated total genes; a high overrepre-
sentation value means that VPA preferentially
deregulates developmental genes. Dp and Di values were
estimated for various fold change values for the develop-
mental genes (> 2, > 5 and > 10). Dp values showed a
linear increase for the same cell line with increasing fold
change, but varied among cell lines. Interestingly, the Di
values were similar for all three cell lines, for any given
fold change value. The greatest increase in Di values
occurred for a fold change from two to five. There also
was a moderate increase in Di from fivefold to tenfold
change in developmental genes, indicating that a fivefold
change for developmental genes is most critical for the
Di calculation. Thus, this index has strong potential for
prediction of developmental toxicants.
Among the VPA-deregulated genes common to all three
cell lines, several developmental genes were of particular
interest for assessing in vivo observed teratogenic effects
of VPA. In particular, we identified two upregulated devel-
opmental genes, which become downregulated by VPA
(DOK6 and BCL2), and two downregulated developmental
genes that become upregulated by VPA (CLDN10 and
PRKCB).
Treatment with VPA during pregnancy in women has
resulted in teratogenic malformations in newborns, in-
cluding neural tube defects, microcephaly, ventricular sep-
tal defects, craniofacial abnormalities, ear abnormalities
and urogenital abnormalities [28]. The gene Docking
Protein 6 (DOK6), a member of the DOK family, plays a
role in Ret tyrosine kinase signalling, which promotes
neurite outgrowth (Crowder et al., 2004). In a mouse
model, knockdown of Dok6 by specific RNAi resulted in
decreased neurite outgrowth (Li et al., 2010). B-cell CLL
lymphoma 2 (BCL2) has been described as a key regulator
of embryonic development. Even though Bcl2 knockout in
mice is not lethal, it still exhibits various malformations
during postnatal development, including growth retard-
ation, smaller ears, atrophic thymus and spleen [29, 30].
Bcl2 knockout mice exhibited progressive degeneration of
motor neurons of the facial region [31]. Claudin 10
(CLDN10) is a downregulated developmental gene that
becomes upregulated by VPA. Gain of function studies in
chicken demonstrate that CLDN10 is crucial for normal
heart tube looping [32]. The Protein Kinase C Beta
(PRKCB) is also upregulated by VPA, and recently, signifi-
cant copy number variation has been found in human
patients with ventricular septal defects [33]. In accordance
with our findings, it has been established that VPA stimu-
lates PRKCB in several cell types [34, 35].
Conclusions
Our results suggest that even though hESCs and hiPSCs
show common and distinct differentiation transcriptomic
profiles, the developmental hazard of the test compounds
can be determined by estimating Di, irrespective of
whether hESCs or hiPSCs are used in the test system.
Both Dp and Di provide a novel approach to quantify the
potential of drugs to cause developmental hazards based
on pluripotent stem cells and transcriptomics. In addition,
we show that key developmental genes deregulated by
VPA may be potential players in the phenotypic malfor-
mations observed after patient treatment with VPA.
Additional files
Additional file 1: Figure S1. Tissue classification based on CellNet
analysis for human embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs). Analysis was performed using the.CEL files
of undifferentiated H9 ESCs, foreskin hiPSCs and IMR90 hiPSCs (day 0), as
well as the differentiated cells (day 14). Although the tissue classification
scores were < 0.2, hESCs and hiPSCs revealed an increase in score during
differentiation (day 14), compared with day 0. Higher tissue classification
scores for neuron, fibroblast, lung, skin and heart tissue were found in
the IMR90 hiPSCs, compared to foreskin hiPSCs and H9 ESCs. Figure S2.
H9 hESCs, IMR90 and foreskin hiPSCs were differentiated for 14 days,
exposed to valproic acid (VPA) during differentiation. Samples collected
on day 0 and day 14, as indicated in Fig. 1a, were used for whole
transcriptome analysis. The data structure of all transcriptome data sets
was dimensionally reduced and presented as a two-dimensional principle
component analysis (2D-PCA) diagram. The PCA illustrates a relatively
large distance between hESCs and hiPSCs on day 0, indicating initial
differences in transcriptome profile, however 14 days of differentiation
resulted in a large distance between day 0 and day 14 in all cell lines,
related to changes along the PC1 axis. Figure S3. Overlap analysis of
“developmental” probe sets (D-PS) in H9 hESCs, IMR90 and foreskin
hiPSCs (for absolute fold change ≥5, p < 0.05) deregulated by VPA. D-PS
were identified, as described in Additional file 2: Table S2 and VPA-affected
genes (T-genes) were identified, as described in Additional file 2: Table S3.
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The overlap of upregulated T-genes with up- (red) and down- (blue) regu-
lated D-PS, as well as the overlap of downregulated T-genes with up- and
downregulated D-PS was calculated for all three cell lines. The data are
expressed as the fraction of D-PS affected by VPA. (PPTX 271 kb)
Additional file 2: Table S1. “Developmental probe sets” significantly
deregulated on day 14 with respect to day 0 for foreskin, IMR90 and H9
cell lines (absolute fold change ≥ 2, false discovery rate-corrected p value
< 0.05). Table S2. “Deregulated probe sets” by valproic acid (VPA) on day
14 with respect to control on day 14 in foreskin, IMR90 and H9 cell lines
(absolute fold change ≥ 2, false discovery rate-corrected p value < 0.05).
Table S3. List of significant biological processes (Gene Ontology categor-
ies; GOs) captured by “upregulated developmental genes” in foreskin,
IMR90 and H9 cell lines (absolute fold change ≥ 2, false discovery rate-
corrected p value < 0.05). Table S4. List of significant biological processes
(Gene Ontology categories; GOs) captured by “downregulated develop-
mental genes” in foreskin, IMR90 and H9 cell lines (absolute fold
change ≥ 2, false discovery rate-corrected p value < 0.05). Table S5. Dif-
ferentially expressed developmental genes belonging to the three germ
layers and deregulated by valproic acid (VPA) (absolute fold change ≥ 2,
false discovery rate-corrected p value < 0.05). Table S6. Probe sets signifi-
cantly deregulated on day 0 among foreskin, IMR90 and H9 cell lines (ab-
solute fold change ≥ 2, false discovery rate-corrected p value < 0.05).
Table S7. List of significant biological processes (Gene Ontology categor-
ies; GOs) captured by valproic acid (VPA) downregulated probe sets on
day 14 in differentiated foreskin, IMR90 and H9 cell lines (absolute fold
change ≥ 2, false discovery rate-corrected p value < 0.05). Table S8. List
of significant biological processes (GOs) captured by valproic acid (VPA)
downregulated probe sets on day 14 in differentiated foreskin, IMR90
and H9 cell lines (absolute fold change ≥ 2, false discovery rate-corrected
p value < 0.05). (XLSX 1225 kb)
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